ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

VYVANSE CHEWABLE TABLETS
ADHD
Anxiety/OCD
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

VYVANSE CHEWABLE TABLETS CII

Generic Name and Formulations:
Lisdexamfetamine dimesylate 10mg, 20mg, 30mg, 40mg, 50mg, 60mg; strawberry-flavored.

Company:
Shire US, Inc.

Therapeutic Use:

Indications for VYVANSE CHEWABLE TABLETS:

Attention deficit hyperactivity disorder.

Adults and Children:

<6yrs: not established. Do not subdivide a single dose. Caps: swallow whole or may open and mix/dissolve contents in yogurt, water, orange juice; take immediately. Chew tabs: chew thoroughly before swallowing. Individualize. ≥6yrs: initially 30mg once daily in AM. May adjust in increments of 10mg or 20mg at weekly intervals; max 70mg/day. Severe renal impairment (GFR 15–<30mL/min/1.73m2): max 50mg/day; ESRD (GFR <15mL/min/1.73m2): max 30mg/day.

Contraindications:

During or within 14 days of MAOIs.

Warnings/Precautions:

Abuse potential (monitor). Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for serotonin syndrome; discontinue if occurs. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Renal impairment. Monitor growth (esp. children), BP, HR. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy; monitor for neonatal withdrawal symptoms. Nursing mothers: not recommended.

Interactions:

See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, busprione, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by urinary alkalinizers (eg, sodium bicarbonate, acetazolamide); avoid. Antagonized by acidifiers (eg, ascorbic acid). May potentiate TCAs or sympathomimetics; adjust dose or use alternatives.

See Also:

VYVANSE

Pharmacological Class:

CNS stimulant.

Adverse Reactions:

Anorexia, anxiety, decreased appetite/weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting, constipation, jitters; hypertension, tachycardia.

Generic Availability:

NO

How Supplied:

Caps, Chew tabs—100

Indications for VYVANSE CHEWABLE TABLETS:

Moderate-to-severe binge eating disorder.

Limitations Of use:

Not indicated for weight loss. Safety and effectiveness not established for treating obesity.

Adult:

Do not subdivide a single dose. Caps: swallow whole or may open and mix/dissolve contents in yogurt, water, orange juice; take immediately. Chew tabs: chew thoroughly before swallowing. Individualize. ≥18yrs: initially 30mg once daily in the AM. May adjust in increments of 20mg at weekly intervals to target dose of 50–70mg/day; max 70mg/day. Discontinue if binge eating does not improve. Severe renal impairment (GFR 15–<30mL/min/1.73m2): max 50mg/day; ESRD (GFR <15mL/min/1.73m2): max 30mg/day.

Children:

<18yrs: not established.

Contraindications:

During or within 14 days of MAOIs.

Warnings/Precautions:

Abuse potential (monitor). Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for serotonin syndrome; discontinue if occurs. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Renal impairment. Monitor growth (esp. children), BP, HR. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy; monitor for neonatal withdrawal symptoms. Nursing mothers: not recommended.

Interactions:

See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, busprione, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by urinary alkalinizers (eg, sodium bicarbonate, acetazolamide); avoid. Antagonized by acidifiers (eg, ascorbic acid). May potentiate TCAs or sympathomimetics; adjust dose or use alternatives.

See Also:

VYVANSE

Pharmacological Class:

CNS stimulant.

Adverse Reactions:

Anorexia, anxiety, decreased appetite/weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting, constipation, jitters; hypertension, tachycardia.

Generic Availability:

NO

How Supplied:

Caps, Chew tabs—100

Sign Up for Free e-newsletters